Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry. These cookies remember information that changes the ...
Health technologies are reshaping healthcare, opening up new ways to care for patients, diagnose conditions earlier, and help ...
NICE is currently consulting on updated evaluation methods through October 2025, working with industry and healthcare partners to refine the assessment framework. The programme will initially focus on ...
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS ...
NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this ...
Adults diagnosed with a functional neurological disorder are supported to manage symptoms that are a part of the disorder in non-specialist care. Adults with symptoms that occur as part of a ...
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based ...
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Healthcare professionals do not use scoring tools to identify which adults with osteoarthritis are eligible for referral for consideration of joint surgery. Evidence for the Oxford Hip and Knee scores ...
There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies ...